We are live on ! Find out more
SPHS

Sophiris Bio, Inc.
SPHS

Delisted

SPHS was delisted on the 11th of March, 2020.

30 hedge funds and large institutions have $5.77M invested in Sophiris Bio, Inc. in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 2930 (+1)

0% more capital invested

Capital invested by funds: $5.76M → $5.77M (+$17.9K)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

94% less call options, than puts

Call options by funds: $1K | Put options by funds: $18K

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
7
Reduced
8
Closed
4
Calls
$1K
Puts
$18K
Net Calls
-$17K
Net Calls Change
-$20K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.58M +$330K +116,520 +26%
SM
2
Sabby Management
Florida
$1.39M -$737K -260,304 -34%
PAI
3
Palo Alto Investors
California
$692K
SMV
4
Sofinnova Management VIII
California
$560K +$566K +200,000 New
OAM
5
Oxford Asset Management
United Kingdom
$491K +$496K +175,198 New
Squarepoint
6
Squarepoint
New York
$248K +$251K +88,600 New
VKH
7
Virtu KCG Holdings
New York
$122K +$2.04K +720 +2%
AL
8
Airain Ltd
Guernsey
$100K -$79.4K -28,033 -44%
Hudson Bay Capital Management
9
Hudson Bay Capital Management
Connecticut
$90K
Millennium Management
10
Millennium Management
New York
$65K -$32.5K -11,480 -33%
AIM
11
Acrospire Investment Management
Illinois
$59K +$1.13K +400 +2%
JP Morgan Chase
12
JP Morgan Chase
New York
$50K -$16.5K -5,828 -25%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$49K -$6.54K -2,308 -12%
Goldman Sachs
14
Goldman Sachs
New York
$44K -$30.2K -10,659 -40%
CAN
15
Cetera Advisor Networks
California
$42K
Geode Capital Management
16
Geode Capital Management
Massachusetts
$31K
LPL Financial
17
LPL Financial
California
$28K
LWAC
18
Laurel Wealth Advisors (California)
California
$28K +$28.3K +10,000 New
UBS Group
19
UBS Group
Switzerland
$26K +$15.1K +5,346 +134%
Royal Bank of Canada
20
Royal Bank of Canada
Ontario, Canada
$17K -$413 -146 -2%
Creative Planning
21
Creative Planning
Kansas
$16K -$55.5K -19,600 -78%
Bank of Montreal
22
Bank of Montreal
Ontario, Canada
$12K +$10.3K +3,620 +525%
Morgan Stanley
23
Morgan Stanley
New York
$8K +$849 +300 +11%
CG
24
Cutler Group
California
$8K +$3.96K +1,400 +93%
EWM
25
Edge Wealth Management
New York
$6K

SPHS Hedge Fund Activity: Q4 2016 in Review

30 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q4 2016, worth a combined $5.77M — up 0.31% from $5.76M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SPHS positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $496K. The largest seller was Sabby Management, cutting an estimated $737K.

  • 30 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q4 2016, up from 29 in Q3 2016.
  • Funds reported $5.77M of Sophiris Bio, Inc. stock for Q4 2016, up 0.31% quarter-over-quarter.
  • 5 funds opened new Sophiris Bio, Inc. positions in Q4 2016 and 4 closed out, a net change of +1 holder.
  • The largest Sophiris Bio, Inc. buyer in Q4 2016 was Oxford Asset Management, an estimated $496K added.
  • The largest Sophiris Bio, Inc. seller in Q4 2016 was Sabby Management, an estimated $737K sold.

Based on aggregated 13F filings for Q4 2016.